drugset / Trial / NCT01237665
IXO (Irinotecan, Xeloda, Oxaliplatin) in Rectal Cancer
Phase 2
Unknown
15 enrolled
Ottawa Hospital Research Institute
Hoffmann-La Roche · collabOttawa Regional Cancer Foundation · collabSanofi · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a prospective open label single-arm, single-institution phase II clinical trial to test the efficacy of neoadjuvant treatment with IXO (Irinotecan, Capecitabine \[Xeloda\], Oxaliplatin) followed by chemoradiotherapy and resection in patients with resectable non-metastatic primary rectal cancer of stage cT3-T4 N0-N2.
Timeline
- Start
- 2010-09
- Primary completion
- 2012-12
- Completion
- 2017-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 950 mg/m2 | Oral |
| Subject | Irinotecan | Small molecule | 160 mg/m2 | Intravenous |
| Subject | Oxaliplatin | Small molecule | 100 mg/m2 | Intravenous |